Developer of an AI-powered platform designed to generate and deploy smart contracts. The company's platform enables developers to create complex smart contracts with ease by using natural language, accelerating development time, and reducing errors.
BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, that specializes in the development of an automated platform for producing and characterizing antibodies. Founded in 2019, BigHat utilizes an AI-guided protein therapeutic platform that combines a wet lab with machine learning techniques. This integration allows drug developers to engineer antibodies and biotherapeutics with enhanced functions and improved biophysical properties. The company's innovative design capabilities aim to create safer and more effective treatments for patients facing complex diseases.
Phaidra, Inc. designs and develops artificial intelligence (AI) solutions for industrial companies in USA. The company was founded in 2019 and is based in Seattle, Washington.
Swadesh is a digital banking experience built from the ground up, specifically for the Indian diaspora. They make it delightful for its customers to invest, remit and manage their money in India from abroad.
Manifold Bio is a biotechnology company that features a platform that enables multiplexed quantitation of protein therapeutic designs, generating unprecedented data throughout the drug development process to unlock measurement-driven design. The company is building a protein barcoding platform to bring the power of multiplexed measurement to the development of protein therapeutics.
It was founded in 2020 and headquartered in Boston, Massachusetts.
Biopharmaceutical research and development company that's an affiliate of Clover Health
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Aspen Neuroscience, Inc. is a private biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Established in 2018, the company utilizes induced pluripotent stem cells to create patient-specific restorative cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version aimed at familial forms of the disease. Aspen Neuroscience combines genomic approaches with stem cell biology to advance its mission of modifying the course of Parkinson's disease through these novel therapeutic strategies.
Parallel Finance is a decentralized finance (DeFi) protocol that offers lending and staking services.
Celsius Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on the development and research of innovative drugs. Established in 2017, the company utilizes single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. This approach allows Celsius Therapeutics to identify critical biomarkers that can enhance patient care and contribute to the creation of transformative medicines. The company's commitment to advancing the understanding of complex diseases positions it as a key player in the biotechnology sector.
SandboxAQ is an enterprise software company that focuses on artificial intelligence and quantum computing solutions. It provides tools designed to tackle significant challenges in various sectors, including life sciences, finance, and cybersecurity. Notably, SandboxAQ offers post-RSA cybersecurity modules that help organizations enhance their security measures through post-quantum cryptography, aligning with emerging standards in the field. The company’s software is built to facilitate cross-disciplinary collaboration, drawing from fields such as physics, computer science, neuroscience, mathematics, and cryptography. By leveraging its Large Quantitative Models (LQMs), SandboxAQ delivers innovative solutions that address real-world business and computational challenges, thereby enabling clients to advance their technological capabilities.
Nucleai Ltd. develops AI-powered pathology platform that is used for satellite image analysis to detect cancer, prostate, breast, and gastrointestinal related diseases. Its platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy, and improving patient care. It serves hospitals and labs in in the United States and Israel. The company was founded in 2017 and is headquartered in Tel Aviv-Yafo, Israel.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Syllable is a developer of a text and voice-based platform designed to enhance communication between healthcare providers and patients. By leveraging artificial intelligence, the platform facilitates interactions regarding primary care, specialty referrals, vaccinations, and general practice information. This technology enables patients to access healthcare information and guidance beyond traditional clinical settings, improving overall communication and patient engagement in their healthcare journeys.
Metaphysic is a creator of a program for creating synthetic media that aims to advance the limits of human expression through ethical use. The company's software reconstructs low-resolution film, makes natural-looking facial representations, enables editing of expressions, facial characteristics, or full faces, and reconstructs low-resolution footage, enabling content makers to use artificial intelligence in their work. Metaphysic was established in 2021 by Chris Ume, Kevin Ume, and Thomas Graham in London, England.
Oxford NanoImaging Limited develops and manufactures microscope. It offers Nanoimager, a single-molecule fluorescence microscope which enables researchers to detect biomolecules, such as protein markers for disease or pathogenic bacteria, and viruses at single copy numbers with single-molecule imaging, 3D, and dual-color super-resolution functionality. It also offers Förster Resonance Energy Transfer microscopy technology that reports distances in real time; direct stochastic optical reconstruction microscopy (dSTORM); and photoactivated localization microscopy (PALM) technology based microscope. Oxford NanoImaging Limited was incorporated in 2016 and is based in London, United Kingdom. The company has additional office in Menlo Park, California.
Nodexus is a Venture- and SBIR-backed biotech startup commercializing the NX One platform to address widespread unmet needs for accessible live single cell isolation in industrial/biopharma, clinical research, and academic sectors. The NX One platform consists of a low-infrastructure, low-cost hardware system and single-use disposable microfluidic cartridges tailored toward live single-cell workflows involving gene editing (e.g. CRISPR engineering), cell line/antibody development, and tumor heterogeneity studies.
Verge Genomics focuses on accelerating drug discovery for neurodegenerative diseases through the use of artificial intelligence and genomic data. The company has developed a platform that leverages machine learning to analyze large datasets, identifying genetic targets and predicting effective therapeutics. By mapping genes associated with various neurodegenerative conditions, Verge aims to discover drugs that can simultaneously target multiple genetic factors. Founded by experts in machine learning and neuroscience, Verge Genomics seeks to improve patient outcomes and reduce the costs associated with pharmaceutical development. The company is based in Mountain View, California, and has formed a strategic alliance with Datavant to enhance its data-driven approach.
Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise-level solutions for voice, video, messaging, and collaboration. Founded in 2011 and based in San Francisco, the company offers a suite of products, including Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, all powered by VoiceAI technology. These tools provide features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics, catering to the growing demand for effective remote communication. Dialpad's clients include notable organizations such as Motorola Solutions and Warby Parker. The company has formed strategic partnerships, including one with SoftBank Corp., and has attracted investments from various venture capital firms. Initially known as Switch Communications, Dialpad rebranded in 2016 to reflect its focus on modern business communication needs, enabling employees to collaborate securely from any device within a unified platform.
Exai Bio is a next-generation liquid biopsy company. Exai bio proprietary RNA and artificial intelligence-based liquid biopsy platform deliver clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
MedArrive, Inc. owns and operates a software-as-a-service technology health platform. It enables healthcare providers to extend care services through integrated care management platform. It also integrates clinical data into electronic medical records software and provides communication and billing capabilities. The company is based in New York, New York.
Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
Mekonos Inc. engages in the design, development, and production of gene and cell therapies. The company develops integrated system-on-a-chip to develop predictive models for discovery and development. It develops MEMS, a technology that allows controlling individual nanoneedles to inject single cells, in a parallel architecture. Also, the company operates a cell-engineering platform. The company was founded in 2017 and is based in San Francisco, California
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
Gretel Labs, Inc. develops an online platform that helps developers to create and share data. It offers data catalog, automate data exposure detection, and fast data cataloging of streaming data for fun and privacy; synthetics; and transformation, real time transformation, and data firewalling. Gretel Labs, Inc. was formerly known as Gretel, Inc. The company was founded in 2019 and is based in Poway, California.
Wise Systems Inc. develops autonomous dispatch and routing software designed to enhance the efficiency of last-mile delivery operations across various industries, including food and beverage, courier, and field service. Founded in 2014 and based in Boston, Massachusetts, the company leverages machine learning to optimize fleet performance and improve customer service. Its platform includes tools such as Scheduler for creating dynamic route plans, Dispatcher for real-time monitoring of delivery progress and performance metrics, and a Customer Portal for tracking orders with accurate ETAs. The software processes millions of data points to make intelligent, real-time decisions, resulting in significant mileage reductions, increased fleet utilization, and a substantial decrease in late deliveries. Wise Systems aims to help customers better manage their delivery logistics by providing flexibility and optimizing routes, thereby enhancing overall operational efficiency.
TRIALSPARK, INC. develops health tech platform. Its platform provides clinical trial sites with monetary compensation, medication, study visits, and study-related tests and procedures. The company was incorporated in 2013 and is based in New York, New York.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
Syllable is a developer of a text and voice-based platform designed to enhance communication between healthcare providers and patients. By leveraging artificial intelligence, the platform facilitates interactions regarding primary care, specialty referrals, vaccinations, and general practice information. This technology enables patients to access healthcare information and guidance beyond traditional clinical settings, improving overall communication and patient engagement in their healthcare journeys.
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
Primer Technologies, Inc. specializes in developing advanced software that employs machine learning and natural language processing to analyze extensive datasets. The company's platform is designed to read and interpret documents in multiple languages, uncover insights, and generate automated reports that rival human analysis. By facilitating the understanding of vast amounts of text data, Primer assists governments and corporations in monitoring and making sense of global information. Founded in 2015 and headquartered in San Francisco, California, Primer aims to bridge the intelligence gap for businesses and enhance their ability to respond to emerging trends in the world.
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.
Phaidra, Inc. designs and develops artificial intelligence (AI) solutions for industrial companies in USA. The company was founded in 2019 and is based in Seattle, Washington.
TwinStrand Biosciences, Inc. is a biotechnology company that specializes in Duplex Sequencing, a technology that significantly enhances the accuracy of DNA sequencing by over 10,000 times. This advanced method enables the detection of ultra-low frequency genomic variants that are often overlooked by conventional sequencing techniques. Founded in 2015 and based in Bellevue, Washington, TwinStrand's technology has diverse applications across various fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company's innovative approach provides researchers and clinicians with essential data to inform critical decisions in clinical medicine and public health, facilitating quicker and clearer insights into complex genetic information.
Current Health Limited manufactures wearable healthcare devices to measure patient’s vitals and to alert in case of emergency. The product identifies unwell patients to make early decisions. The product can be used to measure oxygen saturation, respiration rate, pulse rate, temperature, motion & activity, and posture. Current Health Limited was formerly known as Snap40 Limited and changed its name to Current Health Limited in December 2018. Current Health Limited was founded in 2014 and is based in Edinburgh, United Kingdom.
C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The company's ultra-sensitive liquid biopsy assay will allow physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods.
Meatable B.V. is a food production company based in the Netherlands that specializes in the development of lab-grown meat and meat products derived from cows, chickens, and pigs. Founded in 2018, the company focuses on producing single-cell based hamburgers and aims to address concerns related to climate change, animal welfare, and food security. By utilizing innovative techniques, Meatable seeks to provide a sustainable alternative to traditional meat production, allowing consumers to enjoy real meat without compromising ethical or environmental standards. Through its efforts, the company aspires to satisfy the global demand for meat while promoting a more responsible and guilt-free approach to food consumption.
Miroculus, Inc. manufactures non invasive tools for molecular data gathering, analysis, and interpretation application. The company manufactures novel digital microfluidic technology equipment to automate and miniaturize genomic protocols, such as NGS library prep, synthetic biology, cell editing, and combinatorial chemistry, in a compact, cartridge-based system that is within reach of all laboratories. The company enables clients to detect and monitor disease at the molecular level. It provides solutions for academic institutions and genomic research centers, as well as pharmaceuticals, biotechnology, and diagnostics companies. The company was founded in 2014 and is based in San Francisco, California.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
WithMe Health replaces an employer’s pharmacy benefit manager (PBM) with a medication guidance solution that greatly improves on and expands the scope of services available in the market today.
Our modern technology and rich datasets allow consistent application of proven science to create individualized medication experiences for employees and their families that are proactive, adaptive, convenient and engaging.
With an innovative, outcomes-oriented business model that aligns interests across the pharmaceutical value chain, WithMe Health optimizes health outcomes and value while substantially reducing costs for employers.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.
Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Neocis, Inc. specializes in the development and manufacturing of robotic guidance systems for dental implant procedures. The company is known for its flagship product, Yomi, a precision instrument designed to assist in the placement of dental implants through advanced planning software. Yomi integrates computer imagery from CT scans with the execution of surgical plans, enhancing the capabilities of dental surgeons and improving patient care. This robotic device is commercially available in the United States and has received clearance from the U.S. Food and Drug Administration. Founded in 2009 and headquartered in Miami, Florida, Neocis collaborates closely with dental surgeons to address surgical and treatment challenges in the field of dentistry.
Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise-level solutions for voice, video, messaging, and collaboration. Founded in 2011 and based in San Francisco, the company offers a suite of products, including Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, all powered by VoiceAI technology. These tools provide features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics, catering to the growing demand for effective remote communication. Dialpad's clients include notable organizations such as Motorola Solutions and Warby Parker. The company has formed strategic partnerships, including one with SoftBank Corp., and has attracted investments from various venture capital firms. Initially known as Switch Communications, Dialpad rebranded in 2016 to reflect its focus on modern business communication needs, enabling employees to collaborate securely from any device within a unified platform.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
Glympse Bio, Inc. is focused on developing modular nanoparticle sensors for diagnostics in fibrosis, cancer, immunology, and infectious diseases, as well as for monitoring drug response. The company utilizes engineered diagnostic agents that assess disease states within the body and convey this information to urine for analysis. Its flagship product, Glympse Inside, serves as a pan-disease engine intended to enhance disease monitoring and treatment response. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's innovative platform technology originated at MIT and is backed by a team of experts in nanomedicine and biomedical engineering.
Evidation Health is a provider of a health data analytics platform designed to collect and analyze continuous behavior data and healthcare information so as to create better health outcomes. Its platform turns raw, high-frequency everyday behavior data from sensors, devices, speech, video, and other sources into new knowledge about health and disease, that enable individuals and innovative companies to understand and influence the everyday behaviors.
It was founded in 2012 and is headquartered in San Mateo, California.
Autobahn Therapeutics, Inc. develops small molecule therapies for the treatment of central nervous system (CNS) disorders. The company develops ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS), and adrenomyeloneuropathy (AMN). Autobahn Therapeutics, Inc. was formerly known as Llama Therapeutics, Inc. and changed its name to Autobahn Therapeutics, Inc. in December 2019. The company was incorporated in 2017 and is based in San Diego, California.
Phaidra, Inc. designs and develops artificial intelligence (AI) solutions for industrial companies in USA. The company was founded in 2019 and is based in Seattle, Washington.
Aspen Neuroscience, Inc. is a private biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Established in 2018, the company utilizes induced pluripotent stem cells to create patient-specific restorative cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version aimed at familial forms of the disease. Aspen Neuroscience combines genomic approaches with stem cell biology to advance its mission of modifying the course of Parkinson's disease through these novel therapeutic strategies.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.
Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
XOKind is an artificial intelligence startup based in San Diego, California, founded in 2019. The company focuses on simplifying human planning and decision-making by developing AI software specifically for the travel and leisure markets. XOKind's AI agents learn users' travel preferences by analyzing their calendars, emails, photos, and social media interactions. This innovative approach aims to distill vast amounts of information to provide personalized travel recommendations and streamline the planning process for users.
Aspen Neuroscience, Inc. is a private biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Established in 2018, the company utilizes induced pluripotent stem cells to create patient-specific restorative cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version aimed at familial forms of the disease. Aspen Neuroscience combines genomic approaches with stem cell biology to advance its mission of modifying the course of Parkinson's disease through these novel therapeutic strategies.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
At Cradle Genomics, their mission is to provide knowledge that helps every pregnancy. They're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy.
Cradle Genomics is newly formed with their headquarters based in San Diego and additional R&D operations located in Detroit. Cradle tests are based on the genetic analysis of fetal cells that are quickly collected during a first trimester visit with no risk to the mother or developing fetus.
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
MedCrypt is a cybersecurity company focused on protecting medical devices by providing data security as a service to medical device original equipment manufacturers (OEMs). Founded in 2016 and based in Encinitas, California, MedCrypt's platform incorporates essential security features that ensure medical devices, such as pacemakers and surgical robots, operate only on instructions from trusted sources. The company's solutions include user authentication, data encryption, and transaction monitoring, which help hospitals and health systems prevent unauthorized access and misuse of medical devices. By enabling engineers to integrate these security measures swiftly and efficiently, MedCrypt allows them to concentrate on developing innovative clinical features that can enhance patient care.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Teckro, Inc. offers a solution that transforms clinical trials making all relevant information instantly accessible to every active member of the study. The company facilitates connections between investigators and the expertise they need; and helps study teams, sites, and patients to connect. Its solution instantly captures and shares team’s knowledge to dramatically reduce the burden on CRAs, medical monitors, data management, and study personnel. The company serves pharmaceutical companies and clinical researchers across the world. Teckro, Inc. was incorporated in 2015 and is based in Limerick, Ireland.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
Ciitizen Corporation owns and operates a platform that helps patients collect and share personal health data, such genomic information, labs, ethical wills, and advanced directives. The company was incorporated in 2017 and is based in Palo Alto, California.
Primer Technologies, Inc. specializes in developing advanced software that employs machine learning and natural language processing to analyze extensive datasets. The company's platform is designed to read and interpret documents in multiple languages, uncover insights, and generate automated reports that rival human analysis. By facilitating the understanding of vast amounts of text data, Primer assists governments and corporations in monitoring and making sense of global information. Founded in 2015 and headquartered in San Francisco, California, Primer aims to bridge the intelligence gap for businesses and enhance their ability to respond to emerging trends in the world.
Developer of a current ion source and linear accelerator intended to remove the current limitations of radioisotope manufacturing for medical application and innovation. The company offers a broad range of diagnostic and therapeutic radioisotopes which are produced uranium-free, helping healthcare sector clients develop radiopharmaceuticals for personalized cancer therapies at comparatively lower costs.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing treatments for patients with genetically defined diseases, particularly in areas of high unmet medical need. Headquartered in Cambridge, Massachusetts, the company is advancing its lead product candidate, losmapimod, which is currently in a Phase 2b clinical trial for facioscapulohumeral muscular dystrophy, a rare and progressive muscle-wasting disorder. Additionally, Fulcrum is developing FTX-6058, a small molecule aimed at increasing fetal hemoglobin levels in patients with sickle cell disease and β-thalassemia. The company is also engaged in drug discovery efforts targeting conditions such as Duchenne muscular dystrophy, Friedreich ataxia, and α-synucleinopathies, as well as other neurological and pulmonary diseases. Fulcrum has established collaborations with Acceleron Pharma to explore biological targets in pulmonary diseases and with MyoKardia for the development of therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics is committed to delivering innovative solutions for patients facing significant health challenges.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Metromile is the provider of pay-per-mile car insurance company in the U.S. Powered by data science and machine learning, the company is disrupting a $250 billion auto insurance category. Metromile is building a loyal community of drivers who come for the savings and stay for the experience.
AVA, Metromile's AI-driven claims system, is designed to speed up the process of verifying and paying out insurance claims. Using Metromile Pulse sensor data, AVA can reconstruct the scene of an accident to instantly determine if claim details are accurate. When the claim is verified, Metromile is able to automatically approve payments within seconds.
Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise-level solutions for voice, video, messaging, and collaboration. Founded in 2011 and based in San Francisco, the company offers a suite of products, including Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, all powered by VoiceAI technology. These tools provide features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics, catering to the growing demand for effective remote communication. Dialpad's clients include notable organizations such as Motorola Solutions and Warby Parker. The company has formed strategic partnerships, including one with SoftBank Corp., and has attracted investments from various venture capital firms. Initially known as Switch Communications, Dialpad rebranded in 2016 to reflect its focus on modern business communication needs, enabling employees to collaborate securely from any device within a unified platform.
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
Cue Health Inc. is a San Diego-based healthcare technology company that specializes in the development and manufacturing of medical diagnostic products designed for easy use in various settings, including clinics, schools, and senior living facilities. The company offers the Cue Health Monitoring System, a connected diagnostic platform that allows healthcare professionals to access essential health information through self-serve tests, providing results directly to mobile devices. Additionally, Cue Health provides test cartridges and a consumer software application that features a personalized health dashboard, storing test results and enabling connections to on-demand telemedicine and prescription services. The platform also supports healthcare professionals in managing patient test histories and facilitating follow-up consultations, including telemedicine options. Founded in 2010, Cue Health aims to empower individuals with the ability to track key health indicators, such as inflammation, vitamin D levels, fertility, influenza, and testosterone, at the molecular level from the comfort of their homes.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.
Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Celularity is a developer of therapies designed to treat autoimmune and degenerative diseases, immuno-oncology and functional regeneration. The company's therapies productize allogeneic cells and tissues derived from the postpartum placenta and have the ability to augment immunity and longevity by amplifying the body's ability to fight disease, heal and regenerate itself, enabling patients to begin treatment more quickly, resulting in a better medical outcome.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Dave Inc. is a financial services company based in Los Angeles, California, founded in 2015. The company has developed a mobile application designed to assist users in managing their finances by providing insights into bank overdrafts and predicting expenses. The app enables users to avoid overdraft fees and low balances by offering features such as paycheck advances, budgeting tools, and resources for finding side gigs. With a focus on helping users maintain financial stability, Dave serves approximately 7 million Americans by providing essential tools for budgeting and credit building. The application is accessible on both the App Store and Google Play, positioning Dave as a key player in the challenger bank space.
Lime aims to provide a sustainable solution to the first and last mile transportation problem by helping people move around their cities in an affordable and convenient way while eliminating their carbon footprint. The company empowers future generations to change their behavior so we can save this planet together. From the electric scooter to the e-assist and pedal bike, experience the excitement of Lime’s smart mobility fleet.
Kobalt is an independent music services company that provides technology-driven solutions designed to enhance transparency and efficiency for rights owners in the music industry. The company operates through its Music Publishing, Label Services, and Neighbouring Rights divisions, offering a modern alternative to traditional business models. Kobalt empowers artists, songwriters, and publishers by providing real-time reporting through its Kobalt Portal, along with global licensing management, royalty collection, and digital marketing services. With a workforce of over 275 employees and a client roster that includes prominent artists and songwriters, Kobalt represents more than 8,000 creators and 600,000 songs, significantly impacting the music charts. The company aims to ensure fair and accurate payment for its clients while navigating the complexities of the digital music landscape.
Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise-level solutions for voice, video, messaging, and collaboration. Founded in 2011 and based in San Francisco, the company offers a suite of products, including Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, all powered by VoiceAI technology. These tools provide features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics, catering to the growing demand for effective remote communication. Dialpad's clients include notable organizations such as Motorola Solutions and Warby Parker. The company has formed strategic partnerships, including one with SoftBank Corp., and has attracted investments from various venture capital firms. Initially known as Switch Communications, Dialpad rebranded in 2016 to reflect its focus on modern business communication needs, enabling employees to collaborate securely from any device within a unified platform.
Teckro, Inc. offers a solution that transforms clinical trials making all relevant information instantly accessible to every active member of the study. The company facilitates connections between investigators and the expertise they need; and helps study teams, sites, and patients to connect. Its solution instantly captures and shares team’s knowledge to dramatically reduce the burden on CRAs, medical monitors, data management, and study personnel. The company serves pharmaceutical companies and clinical researchers across the world. Teckro, Inc. was incorporated in 2015 and is based in Limerick, Ireland.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Coinbase, Inc. is an online platform that enables merchants, consumers, and traders to buy, sell, and store digital currencies, including Bitcoin, Ethereum, and Litecoin. Founded in 2012 and based in San Francisco, California, Coinbase provides various products and services, such as a user-friendly website for transactions, digital wallets, and merchant payment processing tools. The platform allows users to connect their bank accounts to facilitate the buying and selling of cryptocurrencies. Additionally, Coinbase Ventures serves as the company's investment arm, focusing on early-stage startups in the cryptocurrency and blockchain sectors. With a mission to create an open financial system for the world, Coinbase has positioned itself as a significant player in the digital currency market.
Auris Health, Inc. is a company based in Redwood City, California, focused on developing advanced robotics technology for medical applications. Founded in 2007, it specializes in creating innovative solutions for diagnostic and therapeutic bronchoscopic procedures. The company's flagship product, the Monarch Platform, utilizes small cameras and instruments to facilitate endoscopic procedures through natural body openings. This platform incorporates cutting-edge advancements in imaging technology, robotics, endoscope design, sensing, and data science, aiming to enhance patient outcomes and reduce medical costs. Additionally, Auris Health is developing a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its capabilities in the medical robotics field. As a subsidiary of Johnson & Johnson, Auris Health continues to transform medical intervention through its integration of various technological innovations.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
BloomAPI strive to democratize access to healthcare data. To unlock a future where all EMRs are interoperable and where vendors can't hold data hostage for their competitive advantage. They are helping to make healthcare technology easier by connecting patients, providers, and payers.
Kobalt is an independent music services company that provides technology-driven solutions designed to enhance transparency and efficiency for rights owners in the music industry. The company operates through its Music Publishing, Label Services, and Neighbouring Rights divisions, offering a modern alternative to traditional business models. Kobalt empowers artists, songwriters, and publishers by providing real-time reporting through its Kobalt Portal, along with global licensing management, royalty collection, and digital marketing services. With a workforce of over 275 employees and a client roster that includes prominent artists and songwriters, Kobalt represents more than 8,000 creators and 600,000 songs, significantly impacting the music charts. The company aims to ensure fair and accurate payment for its clients while navigating the complexities of the digital music landscape.